Relevant bibliographies by topics / Sofosbuvir And Velpatasvir

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers
  5. Reports

Academic literature on the topic 'Sofosbuvir And Velpatasvir'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Sofosbuvir And Velpatasvir.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Sofosbuvir And Velpatasvir"

1

Heo, Jeong, Yoon Jun Kim, Sung Wook Lee, et al. "Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study." Korean Journal of Internal Medicine 38, no. 4 (2023): 504–13. http://dx.doi.org/10.3904/kjim.2022.252.

Full text
Abstract:
Background/Aims: Despite the availability of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in Korea, need remains for pangenotypic regimens that can be used in the presence of hepatic impairment, comorbidities, or prior treatment failure. We investigated the efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for 12 weeks in HCV-infected Korean adults. Methods: This Phase 3b, multicenter, open-label study included 2 cohorts. In Cohort 1, participants with HCV genotype 1 or 2 and who were treatment-naive or treatment-experienced
APA, Harvard, Vancouver, ISO, and other styles
2

Chahine, Elias B., Allana J. Sucher, and Brian A. Hemstreet. "Sofosbuvir/Velpatasvir." Annals of Pharmacotherapy 51, no. 1 (2016): 44–53. http://dx.doi.org/10.1177/1060028016668897.

Full text
Abstract:
Objectives: To review the pharmacology, efficacy, and safety of sofosbuvir/velpatasvir in the treatment of patients with hepatitis C virus (HCV) infection. Data Sources: A literature search through PubMed was conducted (June 2008 to August 2016) using the terms GS-5816, velpatasvir, and sofosbuvir. References from retrieved articles and the prescribing information were reviewed for any additional material. Study Selection/Data Extraction: The literature search was limited to human studies published in English. Phase I, II, and III studies of sofosbuvir/velpatasvir for HCV were identified. Data
APA, Harvard, Vancouver, ISO, and other styles
3

Dr., Rajeswar dutt* Thandu venkateshwarlu Santhosh illendula V.Shirisha. "RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND VELPATASVIR IN COMBINED DOSAGE FORM." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES o6, no. 07 (2019): 13890–903. https://doi.org/10.5281/zenodo.3270795.

Full text
Abstract:
<em>A simple, accurate, precise method was developed for the simultaneous estimation of the Sofosbuvir and Velpatasvir in tablet dosage form. Chromatogram was run through Denali 150 x 4.6 mm, 5</em><em>m</em><em>. Mobile phase containing Buffer 0.01NKH<sub>2</sub>PO<sub>4</sub> (4.8 pH) : Acetonitrile taken in the ratio 65:35 was pumped through column at a flow rate of 1 ml/min. Buffer used in this method was 0.01N KH<sub>2</sub>PO<sub>4</sub> (4.8PH) buffer. Temperature was maintained at 30&deg;C. Optimized wavelength selected was 220.0 nm. Retention time of Sofosbuvir and Velpatasvir were fo
APA, Harvard, Vancouver, ISO, and other styles
4

Nekkala, Kalpana, Shanmukha Kumar J V, Shanmukha Kumar J V, et al. "ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND VELPATASVIR DRUG PRODUCT BY REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD." Asian Journal of Pharmaceutical and Clinical Research 11, no. 2 (2018): 164. http://dx.doi.org/10.22159/ajpcr.2018.v11i2.22465.

Full text
Abstract:
Objectives: The purpose of the research is to develop a simple, precise, economical, accurate, reproducible, and sensitive method for the estimation of sofosbuvir and velpatasvir drug product by rp-hplc methodMethods: New Analytical method was developed for the estimation of Velpatasvir and Sofosbuvir in drug product by liquid chromatography. The chromatographic separation was achieved on C18 column (Luna 18 150*4.6mm3.0um) at ambient temperature. The separation achieved employing a mobile phase consists of 0.1%v/v Formic acid in water: Methanol: Acetonitrile (35:40:25). The flow rate was 0.8m
APA, Harvard, Vancouver, ISO, and other styles
5

Bhatt, Jay. "Analytical method development and validation of related substances by rphplc of sofosbuvir and velpatasvir tablets." Journal of medical pharmaceutical and allied sciences 11, no. 4 (2022): 5201–13. http://dx.doi.org/10.55522/jmpas.v11i4.4051.

Full text
Abstract:
The developed method was a simple, accurate, precise, specific and robust method for the validation of Sofosbuvir and Velpatasvir Tablets by reverse phase high pressure liquid chromatography. For Sofosbuvir and Velpatasvir Tablets Chromatography was performed on Agilent 1200 series, UV and PDA Detector, Waters X-bridge C18 (150 mm x 4.6 mm, 3.5 µm) by using Mobile Phase A contains Buffer solution (0.6% Trifluroacetic acid in water adjusted pH to 2.2±0.05) : Acetonitrile (95:5)%v/v and Mobile Phase B contains mixture of purified water, methanol and acetonitrile in the ratio of (20: 30: 50) % v/
APA, Harvard, Vancouver, ISO, and other styles
6

Ahmed, Tanveer, Omer Hassaan Aftab Ahmad, Muhammad Bilal, Sher Alam, Shirjeel Zaheer, and Zaid Gul. "Comparison of Efficacy of Sofosbuvir & Daclatasvir with Sofosbuvir and Velpatasvir in Achieving SVR in Patients of Chronic Hepatitis C with Genotype 3." Pakistan Journal of Medical and Health Sciences 16, no. 4 (2022): 1155–58. http://dx.doi.org/10.53350/pjmhs221641155.

Full text
Abstract:
Background and Aim: Hepatitis C virus of chronic nature has been appreciated globally to be a major source of hepatic carcinomas and other abnormalities associated with liver function. The epidemiological data on the prevalence of the Hepatitis C virus shows a trend of 71 million people being affected by the disease globally with an annual mortality rate of 3.5 to 5 million death. Pakistan showed a prevalence of up to 8.2% which is among the most common incidents in countries. Since genotype 3 is the most common variant in Pakistan there remains a literature gap that evaluates the effectivenes
APA, Harvard, Vancouver, ISO, and other styles
7

Aya R Hussein, Halder J Abozait, and Nawfal R Hussein. "Successful Sofosbuvir/Velpatasvir retreatment in two pediatric oncology patients with chronic hepatitis C after initial DAA failure: A case report." World Journal of Advanced Research and Reviews 26, no. 2 (2025): 775–78. https://doi.org/10.30574/wjarr.2025.26.2.1733.

Full text
Abstract:
Hepatitis C virus (HCV) infection remains a significant concern for pediatric oncology patients who require multiple blood transfusions. Although direct-acting antiviral (DAA) therapies have revolutionized HCV treatment, recurrence after initial treatment can occur. We report two pediatric oncology patients who experienced HCV relapse after standard DAA regimens but responded successfully to retreatment with sofosbuvir/velpatasvir. Patient 1, a 14-year-old with acute leukemia, was diagnosed with HCV genotype 1. Despite initial successful treatment with ledipasvir/sofosbuvir, HCV RNA reappeared
APA, Harvard, Vancouver, ISO, and other styles
8

Goher Ayub and Brig. Jamal Waris. "Efficacy of Velpatasvir Sofosbovir alone Versus in Combination with Ribavarin in Cirrhotic Patients with Hepatitis C." Indus Journal of Bioscience Research 3, no. 5 (2025): 49–54. https://doi.org/10.70749/ijbr.v3i5.1153.

Full text
Abstract:
Background: Chronic Hepatitis C (HCV) infection is a major cause of liver cirrhosis and its complications. Direct-acting antivirals (DAAs) such as sofosbuvir and velpatasvir have shown high efficacy in treating HCV, but the additional role of ribavirin in combination therapy remains uncertain, particularly in cirrhotic patients. Objective: This study compares the efficacy and safety of sofosbuvir/velpatasvir alone versus in combination with ribavirin in cirrhotic patients with HCV. Methods: This randomized controlled trial was conducted at the Department of Medicine, CMH Kharian. A total of 12
APA, Harvard, Vancouver, ISO, and other styles
9

Bhargavi, S., and B. Sailaja. "Development of Reverse Phase HPLC Method and Validation: Sofosbuvir and Velpatasvir Quantification in Bulk and Tablets." INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE 14, no. 04 (2023): 831–36. http://dx.doi.org/10.25258/ijpqa.14.4.01.

Full text
Abstract:
A new reverse-phase high-performance liquid chromatography (RP-HPLC) method for measuring the amount of sofosbuvir and velpatasvir in active pharmaceutical ingredients (API) and tablet forms has been developed and the method was also validated. Discovery column C18 150 mm x 4.6 mm, pore size of 5 μm was used for the analysis of drugs. Elution of drugs was achieved with 0.1% OPA Buffer: Acetonitrile mixed in the proportion of 40:60 v/v was used as mobile phase, maintaining 1.0 mL/min as flow rate, column temperature maintained at 30°C and uv detector wavelength was fixed at 272 nm. Sofosbuvir a
APA, Harvard, Vancouver, ISO, and other styles
10

Hsu, Po-Yao, Yu-Ju Wei, Jia-Jung Lee, et al. "Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis." Clinical and Molecular Hepatology 27, no. 1 (2021): 186–96. http://dx.doi.org/10.3350/cmh.2020.0180.

Full text
Abstract:
Background/Aims: Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug interactions (DDIs) with DAAs might limit clinical practice in this special population.Methods: The number, class, and characteristics of comedications and their potential DDIs with five DAA regimens were analyzed among HCV-viremic patients from 23 hemodialysis centers in Taiwan.Results: Of 2,015 hemodialysis patients screened in 2019, 169 patients sero
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Sofosbuvir And Velpatasvir"

1

Rydén, Björn. "Hur effektiv och säker är kombinationen av sofosbuvir och velpatasvir mot kronisk hepatit C-infektion." Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-64721.

Full text
Abstract:
Around 130-150 million people are chronically infected with hepatitis C-virus today. Personal suffering and great societal costs aside, this also causes around 400 000 deaths every year due to complications. Earlier treatments with pegylated interferon and ribavirin were both ineffective and had a lot of side effects, but in recent years new treatments using direct-acting antivirals that are both more effective and has less side effects have been introduced. The downside with these are that their effectiveness depends on which HCV genotype the patient has, which requires costly and time consum
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Sofosbuvir And Velpatasvir"

1

Brainard, Diana M., and John G. McHutchison. "The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa®)." In Topics in Medicinal Chemistry. Springer International Publishing, 2019. http://dx.doi.org/10.1007/7355_2018_43.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Stamm, Luisa M., and John G. McHutchison. "The Clinical Development of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX, Vosevi®)." In Topics in Medicinal Chemistry. Springer International Publishing, 2019. http://dx.doi.org/10.1007/7355_2018_49.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"EPCLUSA (Sofosbuvir + Velpatasvir)." In Antibiotics Manual. John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781119220787.ch65.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Sofosbuvir And Velpatasvir"

1

Puebla Villaescusa, A., I. Gozalo Esteve, M. Larrea Vargas, and MJ Fraile Gallart. "5PSQ-032 Successful treatment of chronic hepatitis C infection with crushed sofosbuvir/velpatasvir." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.349.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cáceres-Velasco, C., L. Gómez-Sayago, L. Marín-Ventura, et al. "5PSQ-029 Safe administration of sofosbuvir/velpatasvir in a patient with percutaneous endoscopic gastrostomy." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.346.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Borgia, Sergio, Janet Dearden, Yoav Lurie, et al. "IDDF2019-ABS-0136 Sofosbuvir/velpatasvir for 12 weeks is safe and effective in patients undergoing dialysis." In International Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-iddfabstracts.270.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mangia, Alessandra, Stefano Fagiuoli, Vito Di Marco, et al. "Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset." In 39. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag, 2023. http://dx.doi.org/10.1055/s-0042-1760055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Agarwal, Kosh, Luis Castells, Beat Mullhaupt, et al. "IDDF2018-ABS-0109 SOFOSBUVIR/VELPATASVIR for 12 weeks in genotype 1–4 hcv-infected liver transplant recipients." In International Digestive Disease Forum (IDDF) 2018, Hong Kong, 9–10 June 2018. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2018. http://dx.doi.org/10.1136/gutjnl-2018-iddfabstracts.210.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rodriguez-Reyes, M., JM Sotoca, and D. Soy-Muner. "4CPS-055 Successful sofosbuvir/velpatasvir treatment in a hepatitis C patient receiving chronic antiepileptic therapy: a case report." In 26th EAHP Congress, Hospital pharmacists – changing roles in a changing world, 23–25 March 2022. British Medical Journal Publishing Group, 2022. http://dx.doi.org/10.1136/ejhpharm-2022-eahp.97.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Neo, Jean Ee, Yu Jun Wong, Kai Le Ashley Tiong, and Pooja Devan. "IDDF2024-ABS-0275 Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral-experienced hepatitis c virus patients." In Abstracts of the International Digestive Disease Forum (IDDF), Hong Kong, 10 – 11 August 2024. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2024. http://dx.doi.org/10.1136/gutjnl-2024-iddf.196.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Esteban, Rafael, Kosh Agarwal, Jose Luis Calleja, et al. "IDDF2019-ABS-0134 Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies." In International Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-iddfabstracts.268.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Graf, C., E. Degasperi, R. D'Ambrosio, et al. "Wirksamkeit von Voxilaprevir/Velpatasvir/Sofosbuvir als Retherapie bei Hepatitis-C Patienten mit Versagen auf die vorherige Therapie mit direkt antiviralen Substanzen (DAA)." In Viszeralmedizin 2023 77. Jahrestagung der DGVS mit Sektion Endoskopie Herbsttagung der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie mit den Arbeitsgemeinschaften der DGAV und Jahrestagung der CACP. Georg Thieme Verlag, 2023. http://dx.doi.org/10.1055/s-0043-1771827.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wong, Yu Jun, Rajneesh Kumar, Chen Hua Liu, et al. "IDDF2021-ABS-0167 Real-world efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in NS5A-inhibitor experienced patients: an international multicenter study from Asia." In Abstracts of the International Digestive Disease Forum (IDDF), Hong Kong, 4–5 September 2021. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2021. http://dx.doi.org/10.1136/gutjnl-2021-iddf.99.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Sofosbuvir And Velpatasvir"

1

Hung, Hsuan-Yu, and Chung-Yu Chen. The impact of Sofosbuvir/Velpatasvir/Voxilaprevir treatment on serum hyperglycemia in HCV infections: A Systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.12.0109.

Full text
Abstract:
Review question / Objective: To assess the possible cause of events, the incidence of grade 3 hyperglycemia after treating Sofosbuvir/Velpatasvir/Voxilaprevir in HCV infections. Condition being studied: Sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX) is an effective, safe rescue therapy regimen for patients have previously been treated failure. Initiating Direct-Acting Antiviral (DAA) treatment for HCV infection with diabetes have experienced hypoglycemia, it could improve insulin resistance due to clean HCV. However, some studies shown that SOF/VEL/VOX has Grade 3 hyperglycemia advers
APA, Harvard, Vancouver, ISO, and other styles
2

Hung, Hsuan-Yu, Hui-Hsiung Lai, Hui-Chuan Lin, and Chung-Yu Chen. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C: A network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.7.0055.

Full text
Abstract:
Review question / Objective: P: ("Hepatitis C"[Mesh] AND "Hepacivirus"[Mesh] AND "Hepatitis C, Chronic”[Mesh]) I: (direct acting antiviral OR asunaprevir OR boceprevir OR daclatasvir OR dasabuvir OR elbasvir OR glecaprevir OR grazoprevir OR ledipasvir OR ombitasvir OR paritaprevir OR pibrentasvir OR simeprevir OR sofosbuvir OR telaprevir OR velpatasvir OR voxilaprevir) C: placebo O: ( "Cholesterol, VLDL"[Mesh] OR "Cholesterol, LDL"[Mesh] OR "Cholesterol, HDL"[Mesh] OR "Dyslipidemias"[Mesh] OR "lipoprotein cholesterol ester, human" [Supplementary Concept] OR "lipoprotein cholesterol" [Supplemen
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Sofosbuvir And Velpatasvir' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography